e-therapeutics enters I-O deal with iTeos

UK-based RNA interference specialist e-therapeutics (AIM: ETX) has entered into a research collaboration agreement with Belgian biotech developing novel cancer immunotherapies, iTeos Therapeutics (Nasdaq: ITOS), focussed on the discovery of novel therapeutic approaches and targets in immuno-oncology.

e-therapeutics, whose shares were up 3.4% at 25.75 pence by early afternoon trading, will remain free to explore additional collaborations in the space.

Under the terms of the agreement, e-therapeutics will receive upfront and near-term cash payments material to the revenue of the company. e-therapeutics is also eligible to receive undisclosed milestone payments through pre-clinical and clinical development, in addition to regulatory milestones per program.